RELEVIUM

Pancreatic cancer has the lowest survival rate of all cancers, and is responsible for 95,000 deaths every year in the European Union. Its treatment is generally palliative, aimed at slowing tumor progression and managing symptoms. RELEVIUM's main hypothesis is that the quality of life (QOL) of patients with advanced pancreatic cancer can be significantly improved by reducing pain and cachexia through personalized nutrition, physical activity and pain management strategies, in addition to chemotherapy treatment. To achieve this, RELEVIUM will equip patients with digital tools that facilitate patient-physician communication and enable them to manage their disease themselves. RELEVIUM will use a multi-sensor connected watch and an innovative remote ultrasound patch, AI algorithms for continuous remote monitoring of pain and sarcopenia, as well as for decision support, and apps for patients and caregivers. Together, these tools will provide a stream of evidence on symptom progression and enable physicians to implement personalized care plans. RELEVIUM brings together an interdisciplinary team of experts, and will also involve patients and their caregivers in an iterative co-creation process. The results of the study will translate into recommendations for integrating remote monitoring and improving quality-of-life outcomes in palliative care for advanced pancreatic cancer.